2026: reflecting on the last year’s research progress and looking at what’s ahead
2025 was one of our most exciting years yet for Parkinson’s research. We saw the launch of EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, the start of recruitment for the phase 3 trial of ambroxol, the forging of new strategic partnerships, and much...
Learn more
Cure Parkinson’s iLCT Pipeline Research Acceleration Programme opens new funding call
Cure Parkinson’s is excited to announce the opening of the iLCT Pipeline Research Acceleration Programme for February 2026. We are welcoming applications to investigate secukinumab in an alpha-synuclein model of Parkinson’s. What is the iLCT Pipeline Research Acceleration Programme? Each year, a committee of over…
Cure Parkinson’s welcomes new research committee members and interns
The research committee are an independent group of 16-20 Parkinson’s researchers, clinicians, industry representatives, and people with Parkinson’s that review and assess all our incoming grant funding applications. In 2026, we are excited to welcome several new members and interns to this committee. Who are…
Results from the phase 2 AZA-PD trial are now published
The full results of the AZA-PD study, a phase 2 clinical trial of the immunosuppressive drug azathioprine, have now been published. Although the study did not meet its primary outcome, it does lay the groundwork for future clinical trials of anti-inflammatory drugs, including the ongoing…
Our 2025 Impact Report
Each year, Cure Parkinson’s produces a report to highlight the impact of our research funding in the wider Parkinson’s field and community. This analysis encompasses the previous financial year as well as the charity’s impact since its beginning in 2005. As of March 2025, we…
Cure Parkinsons and Van Andel Institute renew funding for Parkinson’s clinical trial programme
Cure Parkinson’s and Van Andel Institute (VAI) have renewed a funding agreement to support the International Linked Clinical Trials (iLCT) programme, the world’s largest drug repurposing clinical trial initiative for Parkinson’s disease. As part of the three-year agreement, VAI and Cure Parkinson’s each pledge $750,000…